Key facts
- Tres Alchemix’s last known valuation is $16.8M (Sep 2025).
- It has raised $5.8M; the latest was Early Stage VC ($4.4M) in Sep 2025.
- Notable investors include DNX Ventures, Waseda University Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tres Alchemix
- ·The full record, as it builds
Funding rounds
No funding rounds for Tres Alchemix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tres Alchemix
Developer of an AI-powered biotechnology platform designed to build human in silico models that can predict the efficacy and safety of new compounds. The company's platform integrates multimodal and multi-omics data with proprietary quantum chemistry calculations to predict drug pharmacokinetics and pharmacodynamics and analyze how chemicals behave within cells, tissues, and the human body, enabling clients to make the complexity of the human body interpretable.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2023
- Website
- tresalchemix.com/
- Ownership
- Privately Held (backing)
Tres Alchemix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tres Alchemix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tres Alchemix in its N-PORT filings yet. We sweep new filings monthly.